Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB05080_nanopub.RA8ML9J8OY8iiP2CqdLcve2Lp7ExmvEwDsbLyLfAfyuGw#assertion>. }
Showing items 1 to 12 of
12
with 100 items per page.
- drugbank:DB05080 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05080 label "OBE101 [drugbank:DB05080]" assertion.
- drugbank:DB05080 seeAlso DB05080 assertion.
- drugbank:DB05080 description "OBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine. Obecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of obese individuals and for other weight management indications." assertion.
- drugbank:DB05080 identifier "drugbank:DB05080" assertion.
- drugbank:DB05080 title "OBE101" assertion.
- drugbank:DB05080 drugbank_vocabulary:x-cas cas: assertion.
- drugbank:DB05080 drugbank_vocabulary:drugbank-id "DB05080" assertion.
- drugbank:DB05080 bio2rdf_vocabulary:x-identifiers.org DB05080 assertion.
- drugbank:DB05080 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05080" assertion.
- drugbank:DB05080 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05080 bio2rdf_vocabulary:identifier "DB05080" assertion.